Comparative Pharmacology
Head-to-head clinical analysis: BENSULFOID versus LOTUSATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENSULFOID versus LOTUSATE.
BENSULFOID vs LOTUSATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
LOTUSATE is a selective serotonin reuptake inhibitor (SSRI) that inhibits the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin activity in the central nervous system and thereby exerting antidepressant and anxiolytic effects.
Bensulfoid: not a recognized drug. No data available.
100 mg orally twice daily, with or without food.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life is 3.5-4.5 hours in healthy adults; prolonged to 8-10 hours in moderate hepatic impairment, requiring dose adjustment.
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Primarily renal excretion of unchanged drug (65-75%) with 15-20% as glucuronide conjugate; 10-15% eliminated via feces.
Category C
Category C
Topical Antibiotic
Topical Antibiotic